{"product_id":"opko-swot-analysis","title":"Opko SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Strategic Toolkit Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eOpko’s SWOT reveals a biotech company balancing strong diagnostic assets and strategic partnerships against regulatory risks and cash-burn challenges; our full analysis decodes market positioning, pipeline catalysts, and competitive threats to inform investment and strategic choices—purchase the complete SWOT for a professionally formatted Word report and editable Excel tools to plan, pitch, and act with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Partnership with Pfizer for NGENLA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Pfizer collaboration gives OPKO global reach and a royalty stream tied to NGENLA sales, reducing OPKO’s upfront commercialization costs and market risk.\u003c\/p\u003e\n\u003cp\u003ePfizer’s pediatric endocrinology presence accelerates uptake; analysts estimated 2025 NGENLA royalties at ~$60–80M, forming a growing, predictable revenue line.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Multispecific Antibody Platform via ModeX\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe ModeX Therapeutics acquisition gave Opko a multispecific antibody platform that designs molecules engaging multiple targets, boosting efficacy in oncology and antiviral programs; ModeX closed in May 2024 for $250 million up-front and potential milestones, per company filings. The tech outperforms many monoclonal approaches by enabling simultaneous target engagement, reducing resistance pathways, and improving response rates in preclinical models (40–70% tumor reduction cited). Platform flexibility supports a pipeline aiming for 8+ IND-enabling programs across oncology and infectious disease by 2026, creating higher-value, diversified asset potential and licensing opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Business Model Across Healthcare Segments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOPKO Health runs pharmaceuticals, diagnostics, and biologics, which reduced volatility: in 2024 diagnostics generated about $440M in revenue while pharma\/biologics contributed the balance of reported $1.1B total revenue, buffering sector shocks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStreamlined Asset Portfolio and Improved Liquidity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cp\u003eOPKO’s 2025 divestiture of BioReference Health assets to Labcorp raised about $150 million and cut annual operating costs by roughly $40 million, allowing focus on higher-margin diagnostics and therapeutics.\u003c\/p\u003e\n\u003cp\u003eProceeds reduced net debt by ~$120 million and funded R\u0026amp;D without equity dilution, strengthening the balance sheet and preserving shareholder value.\u003c\/p\u003e\n\u003cp\u003eA leaner corporate structure by end-2025 sped decision cycles, enabling targeted investment in late-stage pipeline programs with clearer go\/no-go metrics.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e$150M proceeds from BioReference sale\u003c\/li\u003e\n\u003cli\u003e~$120M net debt reduction\u003c\/li\u003e\n\u003cli\u003e~$40M annual OPEX savings\u003c\/li\u003e\n\u003cli\u003eNon-dilutive R\u0026amp;D funding preserved equity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Intellectual Property and Patent Protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOpko holds over 200 issued patents and 150 pending applications across diagnostics, formulations, and drug delivery, creating a high barrier to entry and protecting revenue streams such as the Rayaldee-related royalties that contributed $58M in 2024.\u003c\/p\u003e\n\u003cp\u003eManagement prioritizes IP defense—legal and R\u0026amp;D spend totaled roughly $72M in 2024—to secure exclusivity in niche endocrinology and oncology markets and extend commercial windows.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e200+ issued patents\u003c\/li\u003e\n\u003cli\u003e150 pending applications\u003c\/li\u003e\n\u003cli\u003e$58M Rayaldee-related 2024 royalties\u003c\/li\u003e\n\u003cli\u003e$72M 2024 R\u0026amp;D + legal spend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOPKO: $1.1B 2024 revenue, ModeX platform, predictable $60–80M NGENLA royalties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOPKO’s Pfizer NGENLA deal plus pediatric reach creates predictable royalties (~$60–80M est. 2025); ModeX acquisition ($250M May 2024) adds multispecific antibody platform targeting 8+ IND programs by 2026; diversified operations drove $1.1B revenue in 2024 with diagnostics ~$440M; BioReference sale (2025) raised $150M, cut $40M OPEX, and cut net debt ~$120M; 200+ patents protect $58M Rayaldee royalties.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 Revenue\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics 2024\u003c\/td\u003e\n\u003ctd\u003e$440M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNGENLA 2025 royalties (est.)\u003c\/td\u003e\n\u003ctd\u003e$60–80M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eModeX upfront\u003c\/td\u003e\n\u003ctd\u003e$250M (May 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBioReference sale\u003c\/td\u003e\n\u003ctd\u003e$150M (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt reduction\u003c\/td\u003e\n\u003ctd\u003e$120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOPEX savings\u003c\/td\u003e\n\u003ctd\u003e$40M\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents issued\u003c\/td\u003e\n\u003ctd\u003e200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRayaldee royalties 2024\u003c\/td\u003e\n\u003ctd\u003e$58M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a strategic overview of Opko’s internal and external business factors, outlining strengths, weaknesses, opportunities, and threats to assess its competitive position and future risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise Opko SWOT snapshot for rapid strategic alignment and stakeholder-ready presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistory of Consistent Operating Losses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpdespite diversified revenue opko health opk reported gaap net losses in and million by r spend of sg near keeping annual margins negative raising investor concerns about a clear path to sustained profitability.\u003e\n\u003c\/pdespite\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Reliance on NGENLA Royalty Performance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa substantial portion of opko health valuation hinges on ngenla royalties from pfizer with analysts in estimating up to pharmaceutical revenue tied that stream if sales plateau top-line could fall sharply. any slowdown u.s. uptake or failure secure international reimbursement payer coverage rates vary and can cut projected by reduce cash flow. has limited control over marketing pricing distribution decisions creating execution risk. this concentration raises volatility downside risk for investors.\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Research and Development Burn Rate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOpko’s ModeX multispecific antibody program drives heavy R\u0026amp;D spending—Opko reported R\u0026amp;D expense of $182.6 million in FY 2024, up 38% year-over-year—tying up cash over multi-year clinical cycles.\u003c\/p\u003e\n\u003cp\u003eSuch capital intensity raises liquidity risk if trials slip or miss endpoints; a single Phase 2 failure could force bridge financing or dilution.\u003c\/p\u003e\n\u003cp\u003eBalancing this burn while pursuing profitability is critical: at end‑2024 Opko held $210 million in cash and short‑term investments, covering roughly 12–18 months of current spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplexity in Managing Disparate Business Units\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOperating across diagnostics, pharmaceuticals, and medical technology gives OPKO Health a complex structure that drove $1.4B total revenue in 2024 but creates management inefficiencies across units.\u003c\/p\u003e\n\u003cp\u003eDistinct regs—FDA for drugs, CMS and CLIA for diagnostics—need specialized focus, which can dilute group strategy and slow decision cycles.\u003c\/p\u003e\n\u003cp\u003eInvestors may misprice OPKO versus pure-plays; 2024 EV\/Revenue of ~3.2x differs from peers in single segments, complicating valuation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue: $1.4B\u003c\/li\u003e\n\u003cli\u003eSegment-specific regs: FDA, CMS, CLIA\u003c\/li\u003e\n\u003cli\u003eEV\/Revenue ~3.2x vs pure-play peers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExposure to Diagnostic Reimbursement Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe diagnostics segment is exposed to reimbursement cuts: Medicare clinical laboratory fee schedule proposals in 2024 suggested up to 10% reductions for some tests, and private payers often follow, squeezing BioReference margins.\u003c\/p\u003e\n\u003cp\u003eLegislative shifts or payer policy changes can sharply reduce per-test revenue; BioReference reported service revenue of $1.1B in 2024, so a 5–10% cut materially hits EBITDA.\u003c\/p\u003e\n\u003cp\u003eThis regulatory uncertainty makes service-based revenue forecasts unpredictable and raises cash-flow volatility for Opko.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMedicare proposal: ~10% cuts (2024)\u003c\/li\u003e\n\u003cli\u003eBioReference service revenue: $1.1B (2024)\u003c\/li\u003e\n\u003cli\u003e5–10% revenue hit → notable EBITDA pressure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOpko cash burn, NGENLA dependence and BioReference cuts risk trigger severe liquidity strain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpopko faces sustained gaap losses high r burn and cash of end covering months revenue concentration royalties pharmaceutical sales bioreference reimbursement risk medicare proposed cuts create liquidity valuation volatility.\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGAAP net loss\u003c\/td\u003e\n\u003ctd\u003e$182M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D + SG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e~$400M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003e$210M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue\u003c\/td\u003e\n\u003ctd\u003e$1.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBioReference revenue\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNGENLA dependency\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/popko\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eOpko SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Opko SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and the file shown is not a sample but the real, editable analysis included in your download. Buy now to unlock the complete, detailed version immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752831955321,"sku":"opko-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/opko-swot-analysis.png?v=1772246204","url":"https:\/\/growthsharematrix.com\/products\/opko-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}